论文部分内容阅读
目的观察阿托伐他汀对急性冠状动脉综合征(ACS)患者行经皮冠状动脉介入术(PCI)后血脂、炎症因子水平及临床心脏事件的影响。方法将100例接受PCI的ACS患者随机分为A组和B组各50例,分别接受阿托伐他汀10mg/d和40mg/d治疗。测定术前,术后4、12、24周血脂和超敏C反应蛋白(hs-CRP)水平,观察心脏事件的发生情况。结果患者术后服用阿托伐他汀24周,2组胆固醇、低密度脂蛋白、甘油三酯和hs-CRP水平及心脏事件的发生情况较术前均有不同程度的下降,且随治疗时间的延长下降幅度更显著(P<0.05)。B组血脂和hs-CRP水平较A组下降幅度更为显著(P<0.05),但2组心脏事件发生情况差异无统计学意义。结论阿托伐他汀对ACS患者PCI术后再狭窄具有预防作用,强化剂量作用更明显,且安全性好。
Objective To observe the effects of atorvastatin on blood lipids, inflammatory cytokines and clinical cardiac events after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS). Methods One hundred patients with ACS undergoing PCI were randomly divided into group A and group B (50 cases each), receiving atorvastatin 10 mg / d and 40 mg / d respectively. Serum lipid and high-sensitivity C-reactive protein (hs-CRP) levels were measured before and 4, 12 and 24 weeks after operation to observe the occurrence of cardiac events. Results Atorvastatin was taken for 24 weeks. The level of cholesterol, low density lipoprotein, triglyceride and hs-CRP in 2 groups and the incidence of cardiac events were all decreased to some extent compared with those before operation. And with the increase of treatment time The decrease was more significant (P <0.05). The levels of serum lipids and hs-CRP in group B were more significantly decreased than those in group A (P <0.05), but there was no significant difference in the incidence of cardiac events between the two groups. Conclusions Atorvastatin has a preventive effect on restenosis after PCI in patients with ACS, and the effect of intensive dose is more obvious and the safety is better.